The current NCCN Guidelines for Bladder Cancer reflect the most up-to-date, evidence-based data relating to the evaluation and management of non–muscle-invasive bladder cancer (NMIBC). The most notable revision to the guidelines this year is the addition of pembrolizumab for a high-risk subset of patients not responding to bacillus Calmette-Guérin (BCG). It is anticipated that current BCG shortages will offer unique opportunities to promote and enhance clinical trials for patients with bladder cancer. Recent efforts to more precisely define BCG-unresponsive disease (adopted by the FDA) have been critical to standardizing definitions and evaluating the efficacy of clinical trials in bladder cancer.
Disclosures: Dr. Spiess has disclosed that he has no relevant financial relationships.
Correspondence: Philippe E. Spiess, MD, MS, FRCS(C), Department of Genitourinary Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Office 12538, Tampa, FL 33612. Email: email@example.com
BabjukM, BurgerM, CompératEM, European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol 2019;76:639–657.3144396010.1016/j.eururo.2019.08.016)| false
KhannaA, YerramN, ZhuH, Utilization of bacillus Calmette-Guerin for nonmuscle invasive bladder cancer in an era of bacillus Calmette-Guerin supply shortages. Urology 2019;124:120–126.10.1016/j.urology.2018.07.055)| false
KamatAM, SylvesterRJ, BöhleA, Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol2016;34:1935–1944.
KamatAM, SylvesterRJ, BöhleA, Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:1935–1944.2681153210.1200/JCO.2015.64.4070)| false